| Application | Recommended Dilution |
|---|---|
| IHC | 1:50-1:200 |
| FC | 1:50-1:200 |
TAB1 (TGF-beta-activated kinase 1-binding protein 1) serves as a critical regulatory component in inflammatory and stress response signaling pathways. As an essential activator of TAK1 (MAP3K7), TAB1 plays a pivotal role in mediating signals downstream of TGF-beta, IL-1, and Toll-like receptors, making it a key focus for researchers investigating innate immunity, inflammatory diseases, and cellular stress responses.
This recombinant monoclonal antibody, clone 11B7, offers the reproducibility and consistency that demanding experimental workflows require. Developed using recombinant technology with a sequence-defined approach, this antibody eliminates the lot-to-lot variability that can compromise longitudinal studies or multi-site collaborations. The rabbit host origin combined with monoclonal specificity ensures reliable detection of human TAB1 across your experimental timeline.
Validation studies demonstrate robust performance in multiple applications, providing flexibility for diverse research needs. Immunohistochemistry testing in paraffin-embedded human stomach tissue using a Leica Bond system with citrate buffer antigen retrieval shows clear specific staining at 1:100 dilution, confirming suitability for tissue-based studies. Flow cytometry analysis in Jurkat cells reveals a distinct positive shift compared to isotype control, with fixed and permeabilized cells showing reliable intracellular detection at 1:100 dilution. These validated applications, along with ELISA compatibility, support comprehensive protein expression analysis from tissue architecture to single-cell resolution.
Supplied in a glycerol-containing buffer optimized for long-term stability, this antibody is well-suited for research programs exploring NF-κB signaling, inflammatory pathway regulation, and TAK1-mediated kinase cascades in human samples.
Email: support@cusabio.com
Distributors Worldwide